OUR DEVELOPMENT PORTFOLIO

 

latest update 10 September 2018

Cardiovascular diseases



Diabetes



Cancer



Immune-
Inflammatory diseases



Neuropsychiatric diseases


Phase 1

Colorectal cancer, 2nd line

Trifluridine/Tipiracil

Cancer

MPS1 inhibitor

Cancer

Mcl1 inhibitor

Cancer

UCART 19

Cancer

DART 123

Cancer

Bcl2 inhibitor

Lung cancer, 2nd line

Nanoliposomal Irinotecan

Cancer, 1st line

mPaCa / Nanoliposomal Irinotecan

Ischemic stroke

TAFIa inhibitor

Chronic heart failure

Anti Mir92a

Muscle diseases

RyR modulator

Phase 2

Venous leg ulcer
Colorectal cancer, 1st line

Trifluridine/Tipiracil

Osteoarthritis

ADAMTS-5

Post stroke

GABA antagonist

Multiple sclerosis

Anti MSRV-Env

Phase 3

Chronic heart failure

Omecamtiv meécarbil

Type 2 diabetes

Exenatide implant

Lymphoma, 2nd line

Pixantrone

Autism

Bumetanide